PFA Pension Forsikringsaktieselskab Purchases Shares of 35,405 Alnylam Pharmaceuticals, Inc. $ALNY

PFA Pension Forsikringsaktieselskab purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 35,405 shares of the biopharmaceutical company’s stock, valued at approximately $14,065,000.

Several other institutional investors also recently modified their holdings of ALNY. Root Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $32,000. Finally, ORG Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $296.11 on Monday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $245.96 and a twelve month high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The stock has a market cap of $39.51 billion, a price-to-earnings ratio of 80.90 and a beta of 0.31. The firm’s 50 day moving average price is $320.11 and its two-hundred day moving average price is $376.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the company posted ($0.44) EPS. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 EPS for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,958 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $2,157,536.64. Following the transaction, the chief executive officer directly owned 85,662 shares in the company, valued at approximately $26,562,072.96. The trade was a 7.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total transaction of $677,530.36. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,058,797.44. The trade was a 8.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 38,656 shares of company stock worth $12,370,696. 0.86% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $471.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.